Evidence map›Paper›PMID 42165412›Full record

ArticleNanomedicine (London, England)2026

Sodium alginate functionalized biocompatible selenium nanocarriers loaded trans-resveratrol for mitochondrial targeted HepG2 hepatocellular carcinoma inhibition study.

Mahvish Fatima, Nosheen Kanwal, Eman Kashita, Muhammad Hammad Aziz, Attalla F El-Kott, Ali A Shati, Mohammad Y Alfaifi, Serag Eldin I Elbehairi, Yasir Iqbal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mahvish FatimaDepartment of Physics, College of Science, Qassim University, Buraydah, Saudi Arabia.
Nosheen KanwalDepartment of Chemistry, College of Science, Qassim University, Almolaydah Buraydah, Saudi Arabia.
Eman KashitaDepartment of Physics, College of Science, Qassim University, Buraydah, Saudi Arabia.
Muhammad Hammad AzizDepartment of Physics, COMSATS University Islamabad, Lahore, Pakistan.
Attalla F El-KottDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Ali A ShatiDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Mohammad Y AlfaifiDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Serag Eldin I ElbehairiDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Yasir IqbalShenzhen Key Laboratory of Biomimetic Robotics and Intelligent Systems, Department of Mechanical and Energy Engineering, Southern University of Science and Technology, Shenzhen, People's Republic of China.ORCID 0009-0006-6850-5912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the use of sodium alginate (SA) for functionalization of selenium nanoparticles (SA@Se NPs) in developing biocompatible nanocarrier to enhance stability, mitochondrial targeting and anticancer efficacy of trans-resveratrol (TRV).

methodsSA@Se NPs were synthesized by chemical reduction method and characterized to evaluate their crystalline structure by X-ray diffraction (XRD), particle size and surface charge. Synthesized SA@Se NPs were evaluated for cumulative TRV release. Cytotoxicity of TRV-SA@Se was assessed against HepG2 and HEK-293T cells by WST-8 assay. Superoxide anion detecton by staining with MitoSOX and calorimmetrically caspases-9/3 activities were evaluated in HepG2 cells.

resultsSA@Se NPs demonstrated the spherical morphology with an average particle size of 23 nm having surface charge -33.65 ± 1.94 mV which slightly neutralized to -27.43 ± 2.11 mV by TRV encapsulation. SA@Se NPs exhibited 64.55 ± 4.5% encapsulation efficiency for TRV and showed cumulative release 74.38 ± 3.75% at pH 5.0 over 24 h. TRV-SA@Se NPs exhibited anticancer activity against HepG2 cells having IC

conclusion

Indexed as

AlginatesCarcinoma, HepatocellularDrug CarriersLiver NeoplasmsMitochondriaNanoparticlesResveratrolSeleniumAntineoplastic AgentsApoptosisBiocompatible MaterialsCaspase 9Glucuronic AcidHEK293 CellsHep G2 CellsHexuronic AcidsAlginatesAntineoplastic AgentsBiocompatible MaterialsCaspase 9Drug CarriersGlucuronic AcidHexuronic AcidsResveratrolSeleniumBiocompatiblecaspases-9/3mitochondrial targetingsodium alginateTrans-resveratrolX-ray diffraction

Identifiers

PMID42165412
PMCPMC13228983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.